Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / CCL27

CCL27

Basics

Aliases:
This biomarker is also known as:
  • IL-11 R-alpha-locus chemokine,
  • ALP,
  • cutaneous T-cell attracting chemokine,
  • small-inducible cytokine A27,
  • PESKY,
  • Skinkine,
  • C-C motif chemokine 27,
  • skinkine,
  • cutaneous T-cell-attracting chemokine,
  • IL-11 Ralpha-locus chemokine,
  • Cutaneous T-cell-attracting chemokine,
  • CTAK,
  • small inducible cytokine subfamily A (Cys-Cys), member 27,
  • CTACK,
  • chemokine (C-C motif) ligand 27,
  • ESKINE,
  • ESkine,
  • CC chemokine ILC,
  • ILC,
  • Small-inducible cytokine A27,
  • SCYA27,

View in BioMuta

Description…

CCL27 is a member of the CC cytokine family, and is involved in immunoregulatory and inflammatory processes. CC cytokines are characterized by two adjacent cysteines. CCL27 functions as a chemotactic factor that attracts skin-associated memory T-lymphocytes. CCL27 may also play a role in mediating homing of lymphocytes to cutaneous sites. CCL27 binds specifically to chemokine receptor 10 (CCR10).

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

CCL27 was present at higher levels among cases compared to controls with reasonable AUC values.

Performance Comment

CCL27 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html